Dosing & Uses
Dosage Forms & Strengths
ophthalmic solution
- 0.01% (Lumigan)
- 0.03% (Latisse, generic)
Elevated Intraocular Pressure
Indicated for reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Lumigan (0.01%): Instill 1 gtt in affected eye qDay in evening
Hypotrichosis of the Eyelashes
Indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness, and darkness
Latisse (0.03%): 1 gtt on disposable sterile applicator and apply evenly along skin of upper eyelid margin at base of eyelasheson each eye once nightly
Safety & efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (4)
- latanoprost
latanoprost, bimatoprost. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
- latanoprostene bunod ophthalmic
bimatoprost, latanoprostene bunod ophthalmic. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
- tafluprost
tafluprost, bimatoprost. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
- travoprost ophthalmic
travoprost ophthalmic, bimatoprost. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
Monitor Closely (31)
- aspirin
bimatoprost, aspirin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- aspirin rectal
bimatoprost, aspirin rectal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- bromfenac ophthalmic
bimatoprost, bromfenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- celecoxib
bimatoprost, celecoxib. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- choline magnesium trisalicylate
bimatoprost, choline magnesium trisalicylate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- diclofenac
bimatoprost, diclofenac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- diclofenac ophthalmic
bimatoprost, diclofenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- diflunisal
bimatoprost, diflunisal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- etodolac
bimatoprost, etodolac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- fenoprofen
bimatoprost, fenoprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- flurbiprofen
bimatoprost, flurbiprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- flurbiprofen ophthalmic
bimatoprost, flurbiprofen ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ibuprofen
bimatoprost, ibuprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ibuprofen IV
bimatoprost, ibuprofen IV. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ibuprofen/famotidine
bimatoprost, ibuprofen/famotidine. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- indomethacin
bimatoprost, indomethacin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ketoprofen
bimatoprost, ketoprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ketorolac
bimatoprost, ketorolac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ketorolac intranasal
bimatoprost, ketorolac intranasal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ketorolac ophthalmic
bimatoprost, ketorolac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- meclofenamate
bimatoprost, meclofenamate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- mefenamic acid
bimatoprost, mefenamic acid. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- meloxicam
bimatoprost, meloxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- nabumetone
bimatoprost, nabumetone. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- naproxen
bimatoprost, naproxen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- nepafenac ophthalmic
bimatoprost, nepafenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- oxaprozin
bimatoprost, oxaprozin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- piroxicam
bimatoprost, piroxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- salsalate
bimatoprost, salsalate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- sulindac
bimatoprost, sulindac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- tolmetin
bimatoprost, tolmetin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
Minor (0)
Adverse Effects
>10%
Conjunctival hyperemia (25-45%)
Growth of eyelashes (15-45%)
Ocular pruritus (15-45%)
1-10%
Ocular dryness (3-10%)
Visual disturbance (3-10%)
Ocular burning (3-10%)
Foreign body sensation (3-10%)
Ocular pain (3-10%)
Pigmentation of the periocular skin (3-10%)
Blepharitis (3-10%)
Cataract (3-10%)
Superficial punctate keratitis (3-10%)
Eyelid erythema (3-10%)
Ocular irritation (3-10%)
Eyelash darkening (3-10%)
Ocular discharge (1-3%)
Tearing (1-3%)
Photophobia (1-3%)
Allergic conjunctivitis (1-3%)
Asthenopia (1-3%)
Increases in iris pigmentation (1-3%)
Conjunctival edema (1-3%)
Frequency Not Defined
Periorbital erythema
Eye swelling
Eyelids: burning sensation, edema, irritation, pruritus
Iris hyperpigmentation
Lacrimation increased
Madarosis and trichorrhexis
Periorbital and lid changes associated with a deepening of the eyelid sulcus
Rash (including macular, erythematous, and pruritic limited to the eyelids and periorbital region)
Skin discoloration (periorbital)
Blurred vision
Postmarketing Reports
Effects on intraocular pressure
Iris pigmentation
Lid pigmentation
Hair growth outside treatment area
Intraocular inflammation
Macular edema
Hypersensitivity
Hordeolum
Trichiasis
Asthma-like symptoms
Dizziness
Dyspnea
Eyelid edema
Hypersensitivity reaction including signs and symptoms of eye allergy and allergic dermatitis
Hypertension
Nausea
Dry skin of the eyelid and/or periocular area
Periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus and eyelid ptosis
Skin exfoliation of the eyelid and/or periorbital area
Lid changes associated with periorbital fat atrophy, leading to skin tightness
Enophthalmos and eyelid retraction
Warnings
Contraindications
Hypersensitivity
Cautions
Macular edema, including cystoid macular edema, reported; the 0.01% strength should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
Prostaglandin analogs, including bimatoprost, reported to cause intraocular inflammation; because these products may exacerbate inflammation, use caution in patients with active intraocular inflammation
The 0.01% strength contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses; contact lenses should be removed prior to instillation and may be reinserted 15 minutes following administration
Bacterial keratitis reported; associated with use of multiple-dose containers of topical ophthalmic products; containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of ocular epithelial surface
May gradually change eyelashes and vellus hair in treated eye; these changes include increased length, thickness, and number of lashes; eyelash changes are usually reversible upon discontinuation of treatment
Potential for hair growth to occur in areas where solution comes in repeated contact with skin surface; carefully blot any excess from the eyelid margin to avoid it running onto cheek or other skin areas
Not recommended for patients <16 years
Pigmentation
- May cause darkening of the iris and lid darkening to periorbital pigmented tissues and eyelashes
- Pigmentation change is due to increased melanin content in melanocytes rather than to increase in number of melanocytes
- After discontinuation of bimatoprost, pigmentation of iris is likely to be permanent, while pigmentation of periorbital tissue and eyelash changes have been reported to be reversible in some patients
- Patients who receive treatment should be informed of possibility of increased pigmentation
- While treatment with 0.01% can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly
Pregnancy & Lactation
Pregnancy
There are no adequate and well-controlled studies in pregnant women; there is no increase in risk of major birth defects or miscarriages based on bimatoprost postmarketing experience; administered during pregnancy only if potential benefit justifies potential risk to fetus
Lactation
Not known whether topical ocular treatment with this product could result in sufficient systemic absorption to produce detectable quantities in human milk; the developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Prostaglandin analog
Lowers intraocular pressure by increasing outflow of aqueous humor through both trabecular meshwork and uveoscleral routes
Eyelash growth is believed to occur by increasing the percent of hairs in, and the duration of the anagen or growth phase
Administration
Absorption: No significant systemic accumulation
Peak plasma time: ≤10 min
Onset of action: 4hr (IOP reduction)
Peak effect: 8-12hr
Peak plasma concentration: 0.08 ng/mL
AUC: 0.09 nghr/mL
Distribution
Protein binding: 88%
Vd: 0.67 L/kg
Metabolism
Oxydation; N-deethylation and glucuronidation
Elimination
Half Life: 45 min
Total blood clearance: 1.5 L/hg/kg
Excretion: Urine (67%); feces (25%)
Administration
Intraocular Administration (Lumigan)
Avoid allowing tip of dispensing container to contact the eye, surrounding structures, fingers, or any other surface to avoid contamination of the solution
Remove contact lenses before instilling eye drops; may reinserted 15 minutes following administration
Administer eye drops at least 5 minutes apart if used concomitantly with other topical ophthalmic drug products to lower intraocular pressure
Topical Administration (Latisse)
Avoid allowing tip of dispensing container to contact the eye, surrounding structures, fingers, or any other surface to avoid contamination of the solution
Ensure the face is clean, makeup and contact lenses are removed
Using disposable applicator, apply evenly along skin of upper eyelid margin at base of eyelashes
Upper lid margin in the area of lash growth should feel lightly moist without runoff; blot any excess solution runoff outside upper eyelid margin with tissue or other absorbent cloth
Dispose of applicator after single use; repeat process for opposite eyelid margin using a new sterile applicator
Do not reuse applicators and do not use any other brush/applicator to apply
Do not apply to lower eyelash line
Additional applications will not increase growth of eyelashes
Upon discontinuation, eyelash growth is expected to return to its pretreatment level
Storage
Store at 2-25ºC (36-77ºF)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Lumigan ophthalmic (eye) - | 0.01 % drops |  | |
| Lumigan ophthalmic (eye) - | 0.01 % drops |  | |
| Lumigan ophthalmic (eye) - | 0.01 % drops |  | |
| bimatoprost ophthalmic (eye) - | 0.03 % drops |  | |
| bimatoprost ophthalmic (eye) - | 0.03 % drops |  | |
| bimatoprost ophthalmic (eye) - | 0.03 % drops |  | |
| bimatoprost ophthalmic (eye) - | 0.03 % drops |  | |
| bimatoprost ophthalmic (eye) - | 0.03 % drops |  | |
| bimatoprost ophthalmic (eye) - | 0.03 % drops |  | |
| bimatoprost ophthalmic (eye) - | 0.03 % drops |  | |
| bimatoprost ophthalmic (eye) - | 0.03 % drops |  | |
| bimatoprost ophthalmic (eye) - | 0.03 % drops |  | |
| bimatoprost ophthalmic (eye) - | 0.03 % drops |  | |
| Latisse base of the eyelashes - | 0.03 % drops |  | |
| Latisse base of the eyelashes - | 0.03 % drops |  | |
| bimatoprost base of the eyelashes - | 0.03 % drops |  | |
| bimatoprost base of the eyelashes - | 0.03 % drops |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
bimatoprost base of the eyelashes
BIMATOPROST SOLUTION - TOPICAL
(bye-MAT-oh-prost)
COMMON BRAND NAME(S): Latisse
USES: This medication is used to treat patients with not enough or inadequate eyelashes. Bimatoprost makes the eyelashes more noticeable by causing more eyelashes to grow and making them longer, thicker, and darker. Bimatoprost is similar to a natural chemical in the body (prostaglandin).Bimatoprost is also used to treat glaucoma. If you are already using or are directed to use bimatoprost to treat glaucoma, be careful not to get this eyelash medication into your eyes. Getting extra bimatoprost in your eyes may make it less effective for treating glaucoma. Talk to your doctor or pharmacist for more details.
HOW TO USE: Read the Patient Information Leaflet provided by your pharmacist before you start using bimatoprost and each time you get a refill. Learn how to properly apply this medication. If you have any questions, consult your doctor or pharmacist.Use this medication once daily in the evening or as directed by your doctor.To apply this medication, first wash your hands and face. Remove any makeup and contact lenses. Contact lenses may be reinserted 15 minutes after applying this medication. Place one drop of this medication onto the provided applicator. Then right away draw the applicator carefully across the skin of the upper eyelid margin at the bottom of the eyelashes going from the inner part of your lash line to the outer part. Blot any excess solution that is applied beyond the eyelid margin. Throw away the applicator after applying the medication. Repeat with a new applicator for the other upper eyelid. This medication is not for use on the lower eyelids.If any medication gets into the eye, do not rinse your eye. It is not likely to cause any harm if this medication gets into the eye, because it is the same medication that is used in the eyes to treat glaucoma.To avoid contamination, do not touch the dropper tip or let it touch your eyelashes or any other surface. Do not rinse the dropper. Replace the dropper cap after each use, and keep the cap tightly closed.Use this medication regularly to get the most benefit from it. To help you remember, use it at the same time each evening. Do not use more of this medication than recommended. Using more will not make this medication work faster. It may take up to 2 months before the full benefits of using this medication are seen.When this medication is stopped, expect the appearance of the eyelashes to return to the way they looked before starting treatment with bimatoprost.It is possible that the effects between your two sets of eyelashes may not be the same. There may be differences in eyelash length, thickness, fullness, color, number or direction of growth. If any of these occur, talk to your doctor.
SIDE EFFECTS: Eye redness/discomfort/itching/dryness or eyelid redness may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.It is possible for hair growth to happen in other areas of your skin where this medication frequently touches. Be sure to wipe any extra medication after applying it to the eyelash margins (see also How to Use section).Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.When the eye drop form of this medication is applied directly into the eyes to treat glaucoma, it may slowly (over months to years) cause brown discoloration of the colored portion of the eye (iris). This form of bimatoprost used to improve eyelash appearance could also have this effect. Also, this medication may cause eyelid changes or a darkening of the skin around the base of the eyelashes. After stopping use, eyelid skin darkening should go away after several weeks to months. However other side effects (such as discoloration of the iris) may be permanent. Tell your doctor if any of these side effects occur.Tell your doctor right away if any of these unlikely but serious side effects occur: eye pain, suspected eye infection (discharge, unusual redness, swelling of eyes), rapid vision changes (such as loss of vision).A very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before using bimatoprost, tell your doctor or pharmacist if you are allergic to it; or to similar drugs (such as latanoprost, travoprost); or if you have any other allergies. This product may contain inactive ingredients (such as preservatives like benzalkonium chloride), which can cause allergic reactions or other problems (such as discoloration of contact lenses). Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: eye pressure problems (such as glaucoma), other eye problems (such as macular edema, iritis, uveitis, lens extraction/aphakia).If you develop a new eye condition (such as infection, eye surgery, eye injury) while using this medication, discuss with your doctor whether you should start using a new bottle.If you are having your eye pressure tested, tell the testing personnel (such as optometrist or ophthalmologist) that you are using this medication.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is not known if this drug passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor or pharmacist first.Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: certain glaucoma eye drops (such as bimatoprost, latanoprost, travoprost).This is not a complete list of possible interactions. Before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: This medicine may be harmful if swallowed. If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Do not share this medication with others.This medication has been prescribed for your current condition only. Do not use it for another condition unless told to do so by your doctor.
MISSED DOSE: If you miss a dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store between 36-77 degrees F (2-25 degrees C) away from light and moisture. Do not store in the bathroom. Keep all medicines away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised February 2022. Copyright(c) 2022 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
